CyR.WilkinsMD

Clotting Disorder, Hemophilia & Bleeding Disorder, Sickle Cell & Other Anemias

Assistant Attending Physician

Overview of Dr. Wilkins

Cy Wilkins, MD is a Hematologist located in New York, NY. His subspecialties include Clotting Disorder, Hemophilia & Bleeding Disorder, and Sickle Cell & Other Anemias. He completed his residency in Internal Medicine at University of Southern California/LAC+USC Medical Center. Following this, Dr. Wilkins pursued fellowships in Hematology and Medical Oncology at Boston University Medical Center, Boston VA Healthcare System (Brockton-West Roxbury), and Memorial Sloan Kettering Cancer Center. Currently, he holds positions as an Assistant Professor at both Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine. Dr. Wilkins is experienced in hematologic oncology, platelet disorders, thrombophilias, factor xi deficiency, and thrombotic disorders. He's also contributed to numerous publications in his field.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(903) 337-1354

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2018
Boston University Medical CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2011 - 2014
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2011, MD
University of DelawareBachelors of Science, Exercise Science, Biological Sciences, 2002 - 2006

Certifications & Licensure

FL State Medical License 2022 - Present
NY State Medical License 2017 - 2026
CT State Medical License 2023 - 2025
NJ State Medical License 2019 - 2025
MA State Medical License 2014 - 2017
CA State Medical License 2012 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of Romiplostim for Chemotherapy Induced Thrombocytopenia Start of enrollment: 2014 Jan 30
Completed
Phase 2
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE Start of enrollment: 2022 May 05
Recruiting
Phase 3
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Start of enrollment: 2022 Sep 27
Recruiting
Phase 3

Publications & Presentations

PubMed

29 citations
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, len...
Katrina M Piedra, Tim J Peterson, Carlyn Tan, Jennifer S. Orozco, Malin Hultcrantz
British Journal of Haematology. 2021-08-15
54 citations
Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.
Gerald A. Soff, Yimei Miao, Gemma Bendheim, Jeanette Batista, Jodi V. Mones
Journal of Clinical Oncology. 2016-05-20
50 citations
A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer.
Montreh Tavakkoli, Cy Wilkins, Jodi V. Mones, Michael J. Mauro
Frontiers in Oncology. 2019-04-26

Journal Articles

Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience
Soff GA, Mones J, Wilkins C, et al., Research and Practice in Thrombosis and Haemostasis, 5/24/2019
Significance of Leukocytosis in Malignancies: A Novel Paradigm Between Leukocytosis, G-CSF, Myeloid-Derived Suppressor Cells and Prognosis.
Tavakkoli, M., Wilkins, C., Mones, J. V., & Mauro, M. J., Blood, 11/21/2018
Efficacy and Thrombotic Adverse Events of Romiplostim Use in Patients with Thrombocytopenia Related to Underlying Malignancies
Li, V. J., Miao, Y., Wilkins, C., & Soff, G. A., Blood 130, no. Suppl 1 (2017): 2324., 12/7/2017
Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal.
Dorff TB, Wilkins C, Hepgur M, Quinn DI, Clin Genitourin Cancer, 4/12/2014
Join now to see all

Abstracts/Posters

Safe and Effective Use of Rivaroxaban for Treatment of Cancer Associated Venous Thromboembolic Disease
Gerald A. Soff, Debra M. M Sarasohn, MD, Eva S Haegler-Laube, MD, Sean M Devlin, PhD, Yimei Miao, BS, Gemma Bendheim, BA, Jeanette Batista, RN, Jonathan Wills, Jodi V ..., ASH Annual Meeting, San Diego, 12/2/2018

Lectures

Cancer-Associated Thrombosis: Anatomic Distribution of the Index Event Is Not a Reliable Predictor of Recurrence Risk
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018